Vicore Pharma Holding AB (publ) announced that the Phase 1 study of C106 has concluded and that Vicore will not continue further development due to a transient increase in blood pressure observed at doses believed to be in the clinically effective range. The Phase 1 study of C106 (NCT05427253), initiated in June 2022, was designed as a double-blind, placebo-controlled, randomized first-in-human study to evaluate safety, tolerability, and pharmacokinetics of single and multiple ascending oral doses of the drug candidate from 5 to 300 mg. While there were no major safety signals or tolerability concerns in the doses tested, an increase in blood pressure was observed at twice-daily doses of 140 mg and higher.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
17.3 SEK | +3.72% | +6.00% | +22.00% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+22.00% | 176M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- VICO Stock
- News Vicore Pharma Holding AB
- Vicore Pharma Holding AB Provides Update Regarding Phase 1 Study of C106